However , this more potent platelet inhibition comes at the cost of a higher bleeding risk .
These recently developed P2Y blockers ( ticagrelor , cangrelor , prasugrel and elinogrel ) provide a more consistent and stronger inhibition of platelets by more efficiently antagonizing the P2Y receptor .
This more potent platelet inhibition comes at the cost of a higher bleeding risk .
These recently developed P2Y blockers ( ticagrelor , cangrelor , prasugrel and elinogrel ) provide a more consistent and stronger inhibition of platelets by more efficiently antagonizing the P2Y receptor .